HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
复制标题
DOI：
10.1007/s11904-010-0071-3
复制
发表时间：
2011-03
影响因子：
4.6
通讯作者：
Kovacs, Andrea
中科院分区：
文献类型：
--
作者：
Operskalski, Eva A;Kovacs, Andrea
World-wide, hepatitis C virus (HCV) accounts for approximately 130 million chronic infections, with an overall 3% prevalence. Four to 5 million persons are co-infected with HIV. It is well established that HIV has a negative impact on the natural history of HCV, including a higher rate of viral persistence, increased viral load, and more rapid progression to fibrosis, end-stage liver disease, and death. Whether HCV has a negative impact on HIV disease progression continues to be debated. However, following the introduction of effective combination antiretroviral therapy, the survival of coinfected individuals has significantly improved and HCV-associated diseases have emerged as the most important co-morbidities. In this review, we summarize the newest studies regarding the pathogenesis of HIV/HCV coinfection, including effects of coinfection on HIV disease progression, HCV-associated liver disease, the immune system, kidney and cardiovascular disease, and neurologic status; and effectiveness of current anti-HIV and HCV therapies and proposed new treatment strategies.
